ClinicalTrials.gg
CompletedNCT05249127COBRAUpdated Oct 1, 2024Results posted

64Cu-SAR-bisPSMA for Identification of Participants With Recurrence of Prostate Cancer (COBRA)

A Phase 1/2 interventional study of 64Cu-SAR-bisPSMA in Biochemical Recurrence of Malignant Neoplasm of Prostate, sponsored by Clarity Pharmaceuticals Ltd. Completed at 5 sites in United States. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-10-01.

Sponsored by Clarity Pharmaceuticals Ltd · Phase 1/2, Interventional, and Diagnostic

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
52
Allocation
Not applicable
Ages
18 Years and older
Sex
Male
01

Study summary

The aim of this study is to determine the safety and efficacy of 64Cu-SAR-bisPSMA and determine the ability of 64Cu-SAR-bisPSMA Positron emission tomography (PET)/computed tomography (CT) to correctly detect the recurrence of prostate cancer in participants with biochemical recurrence of prostate cancer following definitive therapy.

Read the detailed description

Participants with biochemical evidence of recurrence of PC were evaluated with 64CU-SAR-bisPSMA PET/CT (Day 0 and Day 1) and by conventional methodologies up to 180 days later, eg. Histopathology/biopsy, conventional imaging, PSA reduction post focal salvage therapy or radiotherapy with no concomitant androgen deprivation therapy. Three independent central readers blinded to the participant number, the time of the PET/CT scan and the results of the conventional methodologies assessed the 64Cu-SAR-bisPSMA PET/CT. Three separate independent readers assessed the results of the conventional methodologies.

02

Conditions studied

  • Biochemical Recurrence of Malignant Neoplasm of Prostate
03

In context

Lead sponsor

Clarity Pharmaceuticals Ltd is the lead sponsor of 11 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. At least 18 years of age.
  2. Signed .
  3. ≥ 12 weeks as determined by the Investigator.
  4. confirmed adenocarcinoma of prostate per original diagnosis and completed subsequent definitive therapy.
  5. Suspected recurrence of prostate cancer (PC) based on rising Prostate-specific antigen (PSA) after definitive therapy on the basis of:

    1. Post-radical prostatectomy: Detectable or rising PSA that is ≥ 0.2 ng/mL with a confirmatory PSA ≥ 0.2 ng/mL (per American Urological Association recommendation) or
    2. Post-radiation therapy, cryotherapy, or brachytherapy: Increase in PSA level that is elevated by ≥ 2 ng/mL above the nadir (per American Society for Therapeutic Radiology and Oncology-Phoenix consensus definition).
  6. Negative or equivocal findings for PC on conventional imaging performed as part of standard of care workup within 60 days prior to Day 0.
  7. The Eastern Cooperative Oncology performance status 0-2.
  8. Adequate recovery from acute toxic effects of any prior therapy.
  9. Estimated of 30 mL/min or higher.
  10. Adequate liver function.
  11. For participants who have partners of : Partner and/or participant must use a method of with adequate barrier protection.

Exclusion criteria

Exclusion Criteria:

  1. Participants who received other agents within 28 days prior to Day 0.
  2. Participants administered any high energy (>300 kiloelectronvolts (keV)) gamma-emitting radioisotope within 5 physical half-lives prior to Day 0.
  3. Ongoing treatment or treatment within 90 days of Day 0 with any systemic therapy (e.g. androgen-deprivation therapy, antiandrogen, gonadotropin-releasing hormone, luteinizing hormone-releasing hormone agonist or antagonist) for PC.
  4. Known or expected to 64Cu-SAR-bisPSMA or any of its components.
  5. Any serious medical condition or extenuating circumstance which the investigator feels may interfere with the procedures or evaluations of the study.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
52 participants (actual)

Study arms

  • Experimental
    64Cu-SAR-bisPSMA

    Patients will receive a single administration of 200 megabecquerels (MBq) of 64Cu-SAR-bisPSMA.

    Drug: 64Cu-SAR-bisPSMA

Interventions

06

What researchers measure

Primary outcomes

  1. Safety and Tolerability

    Incidence and severity of Treatment-Emergent Adverse Events (TEAE) and Serious Adverse Events. Adverse Events were assessed by CTCAE version 5.0

    Time frame: up to 7 days post injection

  2. Participant-level Correct Detection Rate (CDR)- Day 0

    The percentage of TP participants on the Day 0 scan out of all participants with a Day 0 scan.

    Time frame: Day 0 (1- 4 hours) post injection

  3. Participant-level CDR- Day 1

    The percentage of TP participants on the Day 1 scan out of all participants with a Day 1 scan.

    Time frame: Day 1 (24+/-6 Hours) post injection

  4. Region-level Positive Predictive Value (PPV)- Day 0

    The percentage of TP regions on the Day 0 scan out of all positive regions on the Day 0 scan.

    Time frame: Day 0 (1- 4 hours)

  5. Region-level PPV- Day 1

    The percentage of TP regions on the Day 1 scan out of all positive regions on the Day 1 scan.

    Time frame: Day 1 (24 +/- 6 hours)

Secondary outcomes

  1. Biodistribution of 64Cu-SAR-bisPSMA- SUVmean

    The mean Standardized Uptake Value (SUVmean) in lesions, visceral soft tissue and bone.

    Time frame: Day 0 (1 -4 hours) and Day 1 (24 +/- 6 hours) post injection

  2. Biodistribution of 64Cu-SAR-bisPSMA- SUVmax

    SUVmax in lesions, visceral soft tissue and bone

    Time frame: Day 0 (1-4 hours) and Day 1 (24 +/- 6 hours)

  3. Biodistribution of 64Cu-SAR-bisPSMA- SUVr

    Lesion to Background ratio. SUVmax of the lesion divided by the SUVmean of gluteus background

    Time frame: Day 0 (1-4 hours) and Day 1 (24 +/- 6 hours)

  4. Participant-level PPV

    Percentage of TP participants on the Day 0 or Day 1 scan out of all participants with a positive Day 0 or Day 1 scan.

    Time frame: Day 0 (1-4 hours) and Day 1 (24 +/- 6 hours)

  5. Participant-level Detection Rate (DR)

    Percentage of participants with a positive Day 0 or Day 1 scan out of all participants with a Day 0 or Day 1 scan.

    Time frame: Day 0 (1-4 hours) and Day 1 (24 +/- 6 hours)

  6. Participant-level False Positive Rate (FPR)

    Percentage of false positive (FP) participants on the Day 0 or Day 1 scan out of all participants with a positive Day 0 or Day 1 scan.

    Time frame: Day 0 (1-4 hours) and Day 1 (24 +/- 6 hours)

  7. Region-level FPR

    Percentage of FP regions on the Day 0 or Day 1 scan out of all positive regions on the Day 0 or Day 1 scan.

    Time frame: Day 0 (1-4 hours) and Day 1 (24 +/-6 hours)

  8. Participant-level Discrepant PET Negativity Rate

    Percentage of participants with contradicting Day 0 and Day 1 results for whom the Reference Standard was positive.

    Time frame: Day 0 (1-4 hours) and Day 1 (24 +/-6 hours)

  9. Participant-level True Negative Rate (TNR)

    Percentage of TN participants on the Day 0 or Day 1 scan out of all participants with a negative Day 0 or Day 1 scan.

    Time frame: Day 0 (1-4 hours) and Day 1 (24 +/-6 hours)

  10. Region-level TNR

    Percentage of TN regions on the Day 0 or Day 1 scan out of all negative regions on the Day 0 or Day 1 scan.

    Time frame: Day 0 (1-4 hours) and Day 1 (24 +/- 6 hours)

07

Results

Posted Oct 1, 2024

Participant flow

Dates of recruitment period: 11 Apr 2022 to 23 Jan 2023

Participant flow — Overall Study
Milestone64Cu-SAR-bisPSMA Injection
Started52
Completed32
Not completed20
Withdrew: Protocol violation13
Withdrew: Physician decision4
Withdrew: Withdrawal by subject2
Withdrew: Participant non-compliance1

Outcome measures

PrimarySafety and Tolerability

Incidence and severity of Treatment-Emergent Adverse Events (TEAE) and Serious Adverse Events. Adverse Events were assessed by CTCAE version 5.0

Time frame:
up to 7 days post injection
Reported as:
Count of participants · Participants
Safety and Tolerability
Participants64Cu-SAR-bisPSMA Injection
Any TEAE10
TEAE Grade 1 to 28
TEAE Grade 32
TEAE Grade 4 to 50
TEAE Related to 64Cu-SAR-bisPSMA1
Serious TEAE1
Serious TEAE related to Cu64-SAR-bisPSMA0
TEAE leading to withdrawal from study0
TEAE with fatal outcome0
PrimaryParticipant-level Correct Detection Rate (CDR)- Day 0

The percentage of TP participants on the Day 0 scan out of all participants with a Day 0 scan.

Time frame:
Day 0 (1- 4 hours) post injection
Reported as:
Number · percentage of TP participants
Participant-level Correct Detection Rate (CDR)- Day 0
percentage of TP participants64Cu-SAR-bisPSMA
Reader 126.2 (13.9 to 42.0)
Reader 223.8 (12.1 to 39.5)
Reader 319.0 (8.6 to 34.1)
PrimaryParticipant-level CDR- Day 1

The percentage of TP participants on the Day 1 scan out of all participants with a Day 1 scan.

Time frame:
Day 1 (24+/-6 Hours) post injection
Reported as:
Number · percentage of TP participants
Participant-level CDR- Day 1
percentage of TP participants64Cu-SAR-bisPSMA PET Injection
Reader 133.3 (19.6 to 49.5)
Reader 233.3 (19.6 to 49.5)
Reader 326.2 (13.9 to 42.0)
PrimaryRegion-level Positive Predictive Value (PPV)- Day 0

The percentage of TP regions on the Day 0 scan out of all positive regions on the Day 0 scan.

Time frame:
Day 0 (1- 4 hours)
Reported as:
Number · percentage of TP regions
Region-level Positive Predictive Value (PPV)- Day 0
percentage of TP regions64Cu-SAR-bisPSMA Injection
Reader 141.2 (24.6 to 59.3)
Reader 244.8 (26.4 to 64.3)
Reader 339.1 (19.7 to 61.5)
PrimaryRegion-level PPV- Day 1

The percentage of TP regions on the Day 1 scan out of all positive regions on the Day 1 scan.

Time frame:
Day 1 (24 +/- 6 hours)
Reported as:
Number · percentage of TP regions
Region-level PPV- Day 1
percentage of TP regions64Cu-SAR-bisPSMA Injection
Reader 141.5 (26.3 to 57.9)
Reader 232.7 (20.3 to 47.1)
Reader 343.3 (25.5 to 62.6)
SecondaryBiodistribution of 64Cu-SAR-bisPSMA- SUVmean

The mean Standardized Uptake Value (SUVmean) in lesions, visceral soft tissue and bone.

Time frame:
Day 0 (1 -4 hours) and Day 1 (24 +/- 6 hours) post injection
Reported as:
Mean · g/mL
Biodistribution of 64Cu-SAR-bisPSMA- SUVmean
g/mLSUVmean- Day 0SUVmean - Day 1
Reader 1 All Lesions9.898 ± 5.958815.818 ± 15.0800
Reader 2 All Lesions8.990 ± 5.833914.678 ± 19.4486
Reader 3 All Lesions6.635 ± 3.244714.729 ± 11.1719
Reader 1 Bone Lesions9.188 ± 4.709917.699 ± 10.7888
Reader 2 Bone Lesions8.611 ± 4.279610.503 ± 11.9074
Reader 3 Bone Lesions7.283 ± 4.445619.408 ± 10.9045
Reader 1 Soft Tissue Lesions9.706 ± 6.290715.56 ± 15.5137
Reader 2 Soft Tissue Lesions9.018 ± 6.143215.402 ± 20.2457
Reader 3 Soft Tissue Lesions6.386 ± 3.256514.093 ± 11.4177
SecondaryBiodistribution of 64Cu-SAR-bisPSMA- SUVmax

SUVmax in lesions, visceral soft tissue and bone

Time frame:
Day 0 (1-4 hours) and Day 1 (24 +/- 6 hours)
Reported as:
Mean · g/mL
Biodistribution of 64Cu-SAR-bisPSMA- SUVmax
g/mLSUVmax- Day 0SUVmax- Day 1
Reader 1 All Lesions13.973 ± 8.967122.198 ± 18.6239
Reader 2 All Lesions13.914 ± 10.334222.789 ± 32.3980
Reader 3 All Lesions13.924 ± 7.648333.363 ± 37.7745
Reader 1 Bone Lesions13.05 ± 6.444427.600 ± 17.7468
Reader 2 Bone Lesions14.156 ± 6.051916.660 ± 17.9690
Reader 3 Bone Lesions16.718 ± 5.038037.223 ± 19.9721
Reader 1 Soft Tissue Lesions13.746 ± 9.571421.832 ± 19.2837
Reader 2 Soft Tissue Lesions13.680 ± 11.115024.068 ± 33.7881
Reader 3 Soft Tissue Lesions12.981 ± 8.160632.976 ± 39.5467
SecondaryBiodistribution of 64Cu-SAR-bisPSMA- SUVr

Lesion to Background ratio. SUVmax of the lesion divided by the SUVmean of gluteus background

Time frame:
Day 0 (1-4 hours) and Day 1 (24 +/- 6 hours)
Reported as:
Mean · ratio
Biodistribution of 64Cu-SAR-bisPSMA- SUVr
ratioSUVr - Day 0SUVr - Day 1
Reader 1 All Lesions23.233 ± 14.0537118.051 ± 90.7403
Reader 2 All Lesions23.476 ± 17.3919121.306 ± 160.9991
Reader 3 All Lesions25.448 ± 15.0785181.673 ± 171.6481
SecondaryParticipant-level PPV

Percentage of TP participants on the Day 0 or Day 1 scan out of all participants with a positive Day 0 or Day 1 scan.

Time frame:
Day 0 (1-4 hours) and Day 1 (24 +/- 6 hours)
Reported as:
Number · percentage of TP participants
Participant-level PPV
percentage of TP participantsParticipant-level PPV- Day 0Participant-level PPV- Day 1
Reader 144.0 (24.4 to 65.1)45.2 (27.3 to 64.0)
Rader 243.5 (23.2 to 65.5)40.0 (23.9 to 57.9)
Reader 342.1 (20.3 to 66.5)47.8 (26.8 to 69.4)
SecondaryParticipant-level Detection Rate (DR)

Percentage of participants with a positive Day 0 or Day 1 scan out of all participants with a Day 0 or Day 1 scan.

Time frame:
Day 0 (1-4 hours) and Day 1 (24 +/- 6 hours)
Reported as:
Number · percentage of TP participants
Participant-level Detection Rate (DR)
percentage of TP participantsParticipant-level DR- Day 0Participant-level DR- Day 1
Reader 158.0 (43.2 to 71.8)74.0 (59.7 to 85.4)
Reader 256.0 (41.3 to 70.0)80.0 (66.3 to 90.0)
Reader 344.0 (30.0 to 58.7)58.0 (43.2 to 71.8)
SecondaryParticipant-level False Positive Rate (FPR)

Percentage of false positive (FP) participants on the Day 0 or Day 1 scan out of all participants with a positive Day 0 or Day 1 scan.

Time frame:
Day 0 (1-4 hours) and Day 1 (24 +/- 6 hours)
Reported as:
Number · percentage of FP participants
Participant-level False Positive Rate (FPR)
percentage of FP participantsParticipant-level FPR- Day 0Participant-level FPR- Day 1
Reader 153.8 (33.4 to 73.4)54.8 (36.0 to 72.7)
Reader 254.2 (32.8 to 74.4)60.0 (42.1 to 76.1)
Reader 357.9 (33.5 to 79.7)50.0 (29.1 to 70.9)
SecondaryRegion-level FPR

Percentage of FP regions on the Day 0 or Day 1 scan out of all positive regions on the Day 0 or Day 1 scan.

Time frame:
Day 0 (1-4 hours) and Day 1 (24 +/-6 hours)
Reported as:
Number · percentage of FP regions
Region-level FPR
percentage of FP regionsRegion-level FPR-Day 0Region-level FPR-Day 1
Reader 158.8 (40.7 to 75.4)57.1 (41.0 to 72.3)
Reader 255.2 (35.7 to 73.6)67.3 (52.9 to 79.7)
Reader 360.9 (38.5 to 80.3)56.7 (37.4 to 74.5)
SecondaryParticipant-level Discrepant PET Negativity Rate

Percentage of participants with contradicting Day 0 and Day 1 results for whom the Reference Standard was positive.

Time frame:
Day 0 (1-4 hours) and Day 1 (24 +/-6 hours)
Reported as:
Number · percentage of participants
Participant-level Discrepant PET Negativity Rate
percentage of participants64Cu-SAR-bisPSMA Injection
Reader 114.3 (1.8 to 42.8)
Reader 221.4 (4.7 to 50.8)
Reader 342.9 (17.7 to 71.1)
SecondaryParticipant-level True Negative Rate (TNR)

Percentage of TN participants on the Day 0 or Day 1 scan out of all participants with a negative Day 0 or Day 1 scan.

Time frame:
Day 0 (1-4 hours) and Day 1 (24 +/-6 hours)
Reported as:
Number · percentage of TN participants
Participant-level True Negative Rate (TNR)
percentage of TN participantsParticipant-level TNR- Day 0Participant-level TNR- Day 1
Reader 150.0 (30.6 to 69.4)39.3 (21.5 to 59.4)
Reader 253.6 (33.9 to 72.5)25.0 (10.7 to 44.9)
Reader 360.7 (40.6 to 78.5)57.1 (37.2 to 91.8)
SecondaryRegion-level TNR

Percentage of TN regions on the Day 0 or Day 1 scan out of all negative regions on the Day 0 or Day 1 scan.

Time frame:
Day 0 (1-4 hours) and Day 1 (24 +/- 6 hours)
Reported as:
Number · percentage of TN regions
Region-level TNR
percentage of TN regionsRegion-level TNR-Day 0Region-level TNR- Day 1
Reader 188.7 (83.1 to 93.0)86.4 (80.5 to 91.1)
Reader 291.0 (85.7 to 94.7)80.1 (73.4 to 85.7)
Reader 392.1 (87.2 to 95.6)90.4 (85.1 to 94.3)

Adverse events

Collected over Up to 7 days post injection. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Safety Analysis Set0/52 (0%)1/52 (1.9%)0/52 (0%)
Most frequent serious events
Most frequent serious events
EventSafety Analysis Set
urosepsisInfections and infestations1/52

Baseline characteristics

All enrolled participants who received any amount of 64Cu-SAR-bisPSMA.

Age, Categorical
Age, Categorical(Participants)64Cu-SAR-bisPSMA Injection
<=18 years0
Between 18 and 65 years13
>=65 years39
Sex: Female, Male
Sex: Female, Male(Participants)64Cu-SAR-bisPSMA Injection
Female0
Male52
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)64Cu-SAR-bisPSMA Injection
Hispanic or Latino7
Not Hispanic or Latino45
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)64Cu-SAR-bisPSMA Injection
American Indian or Alaska Native0
Asian0
Native Hawaiian or Other Pacific Islander0
Black or African American2
White49
More than one race0
Unknown or Not Reported1
Region of Enrollment
Region of Enrollment(participants)64Cu-SAR-bisPSMA Injection
United States52
Baseline PSA
Baseline PSA(ng/mL)64Cu-SAR-bisPSMA Injection
Mean2.973 ± 4.1722
08

Study locations

5 sites
  • Tower Urology
    Los Angeles, California 90048, United States
  • GU Research Network
    Omaha, Nebraska 68130, United States
  • New Mexico Cancer Center
    Albuquerque, New Mexico 87109, United States
  • Carolina Urologic Research Center
    Myrtle Beach, South Carolina 29572, United States
  • Urology San Antonio
    San Antonio, Texas 78258, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Apr 2022 to primary completion in Aug 2023, 15 months.

Results were first posted in Oct 2024, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 2, 2022
First posted
Feb 21, 2022
StartActual
Apr 11, 2022
Primary completionActual
Aug 8, 2023
CompletionActual
Aug 8, 2023
Results first posted
Oct 1, 2024
Last update
Oct 1, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 1, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05249127
Lead sponsor
Clarity Pharmaceuticals Ltd
Responsible party
Sponsor
First posted
Feb 21, 2022
Start date
Apr 11, 2022
Primary completion
Aug 8, 2023
Completion
Aug 8, 2023
Results posted
Oct 1, 2024
Last update
Oct 1, 2024

Study contacts

Othon Gervasio
study director · Clarity Pharmaceuticals

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Abefolastat tesaroxetan CU-64

Start the discussion